18F-FDG retention index and biologic prognostic parameters in breast cancer

Clinical Nuclear Medicine

Volumn 37, Issue 5, 2012, Pages 460-466

  García Vicente, Ana María ^a   Castrejón, Ángel Soriano ^a   Relea Calatayud, Fernanda ^a   Muñoz, Azahara Palomar ^a   León Martín, Antonio Alberto ^a   López Muñiz, Ignacio Chacón ^b   Del Mar Muñoz Sánchez, María ^c   Cordero García, José Manuel ^a   Becerra Nakayo, Edward Mitsuro ^a  

^a University General Hospital   (Spain)

^b HOSPITAL VIRGEN DE LA SALUD   (Spain)

^c Virgen de la Luz Hospital   (Spain)

Author keywords

breast cancer; fluorodeoxyglucose; PET CT; retention index

Indexed keywords

ESTROGEN RECEPTOR; FLUORODEOXYGLUCOSE F 18; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN P53; DIAGNOSTIC AGENT;

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CANCER STAGING; CELL PROLIFERATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CORRELATION ANALYSIS; DRUG UPTAKE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MAMMOGRAPHY; METABOLIC PARAMETERS; MULTICENTER STUDY (TOPIC); PROTEIN EXPRESSION; QUALITATIVE ANALYSIS; BREAST TUMOR; CLINICAL TRIAL; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PROGNOSIS; SCINTISCANNING;

BREAST NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MIDDLE AGED; PROGNOSIS;

EID: 84859628008     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0b013e31823926c9     Document Type: Article

References (25)

1. Eberlein TJ. Current management of carcinoma of the breast. Ann Surg. 1994;2:121-136. (Pubitemid 24309410)
2. Crippa F, Agrest R, Seregni E, et al. Prospective evaluation of [18F]FDG positron emission tomography (PET) in the presurgical staging of the axilla in breast cancer: comparison between PET and postoperative pathology. J Nucl Med. 1998;39:4-8. (Pubitemid 28063164)
3. Zytoon AA, Murakami K, El-Kholy MR, et al. Dual time point FDG-PET/CT imaging. Potential tool for diagnosis of breast cancer. Clin Radiol. 2008;63: 1213-1227.
4. Mavi A, Urhan M, Yu JQ, et al. Dual time point 18F-FDG PET imaging detects breast cancer with high sensitivity and correlates well with histologic subtypes. J Nucl Med. 2006;47:1440-1446. (Pubitemid 47544929)
5. Zytoon AA, Murakami K, El-Kholy MR, et al. Breast cancer with low FDG uptake: characterization by means of dual-time point FDG-PET/CT. Eur J Radiol. 2009;70:530-538.
6. Gil-Rendo A, Martínez-Regueira F, Zornoza G, et al. Association between [18F] fluorodeoxyglucose uptake and prognostic parameters in breast cancer. Br J Surg. 2009;96:166-170.
7. Buck A, Schirrmeister H, Kühn T, et al. FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters. Eur J Nucl Med. 2002;29:1317-1323. (Pubitemid 44392212)
8. Avril N, Menzel M, Dose J, et al. Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis. J Nucl Med. 2001;42:9-16. (Pubitemid 32104770)
9. Basu S, Chen W, Tchou J, et al. Comparison of triple-negative and estrogen receptorpositive/ progesterone receptor positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters. A potentially useful method for disease characterization. Cancer. 2008;112:995-1000. (Pubitemid 351304582)
10. Shimoda W, Hayashi M, Murakami K, et al. The relationship between FDG uptake in PET scans and biological behavior in breast cancer. Breast Cancer. 2007;14:260-268.
11. García Garzón JR, Rodríguez A, Cabrera A. Tomografía por emisión de positrones de cuerpo completo (PET/TAC) con 18F-fluorodesoxiglucosa. Rev Esp Med Nucl. 2009;28:85-89.
12. Available at: http://www.cancerstaging.org/staging/index.html.
13. Heudel P, Cimarelli S, Montella A, et al. Value of PET-FDG in primary breast cancer based on histopathological and immunohistochemical prognostic factors. Int J Clin Oncol. 2010;15:588-593.
14. Inoue T, Yutani K, Taguchi T, et al. Preoperative evaluation of prognosis in breast cancer patients by [(18)F]2-deoxy-2-fluoro-D-glucose-positron emission tomography. J Cancer Res Clin Oncol. 2004;130:273-278. (Pubitemid 38680268)
15. Uematsu T, Kasami M, Yuen S. Comparison of FDG PET and MRI for evaluating the tumor extent of breast cancer and the impact of FDG PET on the systemic staging and prognosis of patients who are candidates for breast-conserving therapy. Breast Cancer. 2009;16:97-104.
16. Groheux D, Giacchetti S, Moretti JL, et al. Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging. 2011;38:426-435.
17. Basu S, Mavi A, Cermik T, et al. Implications of standardized uptake value measurements of the primary lesions in proven cases of breast carcinoma with different degree of disease burden at diagnosis: does 2-deoxy-2-[F-18] fluoro- D-glucose-positron emission tomography predict tumor biology? Mol Imaging Biol. 2008;10:62-66.
18. Dehdashti F, Mortimer JE, Siegel BA, et al. Positron tomographic assessment of estrogen receptors in breast cancer: a comparison with FDG-PET and in vitro receptor assays. J Nucl Med. 1995;36:1766-1774.
19. Crippa F, Seregni E, Agresti R, et al. Association between F-18 fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: a preliminary observation. Eur J Nucl Med. 1998;25:1429-1434. (Pubitemid 28464119)
20. Zhuang H, Pourdehnad M, Lambright ES, et al. Dual time point F-18-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med. 2001;42:1412-1417. (Pubitemid 32852620)
21. Kubota K, Itoh M, Ozaki K, et al. Advantage of delayed whole-body FDG-PET imaging for tumour detection. Eur J Nucl Med. 2001;28:696-703.
22. Conrad GR, Sinha P. Narrow time-window dual-point F-18-FDG PET for the diagnosis of thoracic malignancy. Nucl Med Commun. 2003;24:1129-1137. (Pubitemid 39625398)
23. Wahl RL, Siegel BA, Coleman RE, et al. Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group. J Clin Oncol. 2004;22:277-285. (Pubitemid 41095092)
24. Veronesi U, De Cicco C, Galimberti VE, et al. A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases. Ann Oncol. 2007;18:473-478. (Pubitemid 46359625)
25. Heusner TA, Kuemmel S, Hahn S, et al. Diagnostic value of full-dose FDG-PET/CT for axillary lymph node staging in breast cancer patients. Eur J Nucl Med Mol Imaging. 2009;36:1543-1550.